NVCT · NASDAQ · Biotechnology

Nuvectis Pharma (NVCT)

Develops licensed small-molecule programs across complement disease and kinase-targeted oncology.

$24.00
At close+0.94 (+4.08%)

Something off on this page? Send us feedback.

Next report
Nov 3, 2026
in 61 days
EPS estimate
−$0.22
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported−$0.36−$0.27−$0.30−$0.44−$0.31−$0.26−$0.30Pending
Estimate−$0.28−$0.30−$0.25−$0.24−$0.26−$0.30−$0.26−$0.22
Surprise−28.6%+10.0%−20.0%−83.3%−19.2%+13.3%−14.5%

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.22
Aug 2026−$0.26−$0.30−14.5%
May 2026−$0.30−$0.26+13.3%
Feb 2026−$0.26−$0.31−19.2%
Nov 2025−$0.24−$0.44−83.3%

The latest year is open to everyone — the 18 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Feb 2025
Nov 2024
Aug 2024
May 2024
Mar 2024
Nov 2023
Aug 2023
May 2023
Mar 2023
Nov 2022
Aug 2022
May 2022
Feb 2022
Jan 2022
Jun 2021
Mar 2021
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 3, 2026−$0.22
Aug 4, 2026−$0.26−$0.30−14.5%−6.9%
May 5, 2026−$0.30−$0.26+13.3%+3.0%
Feb 11, 2026−$0.26−$0.31−19.2%+0.2%
Nov 4, 2025−$0.24−$0.44−83.3%−3.9%

The latest year is open to everyone — the 18 quarters behind it read with an account.

Sign in
Aug 5, 2025
May 6, 2025
Feb 25, 2025
Nov 5, 2024
Aug 6, 2024
May 7, 2024
Mar 5, 2024
Nov 8, 2023
Aug 9, 2023
May 10, 2023
Mar 7, 2023
Nov 8, 2022
Aug 5, 2022
May 10, 2022
Feb 7, 2022
Jan 14, 2022
Jun 30, 2021
Mar 31, 2021